Medicine Description synjardy 12.5/1000mg
synjardy 12.5/1000mg tablets is a medication that combines empagliflozin and metformin to effectively manage blood glucose levels in individuals with type 2 diabetes. Empagliflozin, an SGLT2 inhibitor, works by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion in urine. This process not only lowers blood sugar but also promotes weight loss and may positively impact cardiovascular health. Metformin, on the other hand, enhances insulin sensitivity and decreases hepatic glucose production. Together, these compounds provide a synergistic effect, improving glycemic control and offering additional benefits relevant to diabetes management.
Indications and Uses of synjardy 12.5/1000mg tablets
- Management of type 2 diabetes mellitus in adults
- As an adjunct to diet and exercise to improve glycemic control
Side Effects of synjardy 12.5/1000mg tablets
- Gastrointestinal disturbances such as nausea and diarrhea
- Hypoglycemia when used with other antidiabetic medications
- Urinary tract infections
- Genital fungal infections
- Potential for lactic acidosis, a rare but serious complication
Storage and Handling
Store at room temperature, between 20°C to 25°C (68°F to 77°F). Protect from excessive moisture and heat. Keep out of reach of children.
Patient Advice and Precautions
Monitor blood sugar levels regularly. Maintain a balanced diet and engage in regular physical activity. Be aware of signs of low blood sugar and how to manage it. Consult your healthcare provider before starting any new medications or supplements. Regular follow-ups are essential to assess kidney function and adjust treatment as necessary.